Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

53.61 USD -1.54 (-2.79%)
Official Closing Price Updated: 4:34 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Bioxcel Therapeutics Inc

< Previous 1 2 3 4 Next >
BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation
Topline results are expected in Q1 2022 
From GlobeNewswire News Releases
BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary
From GlobeNewswire News Releases
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms
Live webcast to be held on February 19th from 11:00 am ET to 2:00 pm ET 
From GlobeNewswire News Releases
BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
From GlobeNewswire News Releases
BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease
From GlobeNewswire News Releases
BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD
Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse 
From GlobeNewswire News Releases
BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
From GlobeNewswire News Releases
BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders
From GlobeNewswire News Releases
BioXcel Therapeutics to Present BXCL701 Clinical Data at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting
From GlobeNewswire News Releases
BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast
From GlobeNewswire News Releases
BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium
Fifth potential indication for BXCL501, an orally dissolving thin film 
From GlobeNewswire News Releases
BioXcel Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
From GlobeNewswire News Releases
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
BioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and Webcast
From GlobeNewswire News Releases
BioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth Conference
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation
Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation 
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation
Patent is expected to extend IP protection until 2039 
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development Officer
Will lead global clinical development strategy and medical affairs for the Company’s neuroscience programs 
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial Officer
Former Allergan Commercial Head to lead commercialization efforts for BXCL501 across multiple neuropsychiatric disorders 
From GlobeNewswire News Releases
BioXcel Therapeutics to Participate in Two Upcoming Investor Conferences
From GlobeNewswire News Releases
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms
Topline results expected in the first quarter of 2021 
From GlobeNewswire News Releases
Thinking about trading stocks or options in BioXcel Therapeutics, Tesla, Target, Boeing, or Norwegian Cruise Line?
InvestorsObserver issues critical PriceWatch Alerts for BTAI, TSLA, TGT, BA, and NCLH. 
From PR Newswire
BioXcel Therapeutics to Present at the Jefferies Virtual Healthcare Conference
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501
Topline results, expected in July of 2020, are intended to support a New Drug Application filing 
From GlobeNewswire News Releases
BioXcel Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.